new glp-1 drugs How medications are transforming diabetes and weight loss treatment Emerging Weight Loss Drugs and

Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M

This suggests GLP-1 resistance emerges further downstream

Daniel Drucker [Biomarker April 2023] To date, the adverse event profile of GLP-1R agonists is characterized by relatively mild gastrointestinal (GI) side effects, such as nausea, vomiting, and diarrhea

The STEP UP trial reported an average weight loss of 20.7% at the 7.2mg dose, with 31% of participants losing 25% or more

: Wegovy an adjunct to diet and exercise to reduce body weight an maintain weight reduction to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight

Obesity is also a major driver of non-communicable diseases such as cardiovascular disease and some cancers